Bioventus Inc. Sample Contracts

BIOVENTUS INC. INDEMNIFICATION AGREEMENT
Indemnification Agreement • February 4th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20[21] between Bioventus Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).

AutoNDA by SimpleDocs
AMENDMENT NO. 1 TO THE FIRST LIEN CREDIT AGREEMENT
Credit Agreement • July 19th, 2016 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

FIRST LIEN CREDIT AGREEMENT (this “Agreement”), dated as of October 10, 2014, among BIOVENTUS LLC, a Delaware limited liability company (the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (the “Lenders”) and JPMORGAN CHASE BANK, N.A., as administrative agent.

BIOVENTUS LLC SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of February 16, 2021
Limited Liability Company Agreement • February 17th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

This SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”), dated as of February 16, 2021, is entered into by and among Bioventus LLC, a Delaware limited liability company (the “Company”), and its Members (as defined herein).

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • February 17th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of February 16, 2021, by and among Bioventus Inc., a Delaware corporation (the “Corporation”), and each Person identified on the Schedule of Investors attached hereto as of the date hereof (such Persons, collectively, the “Original LLC Owners”).

TAX RECEIVABLE AGREEMENT by and among BIOVENTUS INC. BIOVENTUS LLC and the MEMBERS (as defined herein) Dated as of February 16, 2021
Tax Receivable Agreement • February 17th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

This TAX RECEIVABLE AGREEMENT (this “Agreement”), dated as of February 16, 2021, is hereby entered into by and among Bioventus Inc., a Delaware corporation (the “Corporation”), Bioventus LLC, a Delaware limited liability company (the “LLC”) and Smith & Nephew, Inc., a Delaware corporation (“S&N”). Capitalized terms used but not otherwise defined herein have the respective meanings set forth in Section 1.01.

AGREEMENT AND PLAN OF MERGER by and among: BIOVENTUS INC., a Delaware corporation; OYSTER MERGER SUB I, INC., a Delaware corporation; OYSTER MERGER SUB II, LLC, a Delaware limited liability company; and MISONIX, INC. a Delaware corporation Dated as of...
Agreement and Plan of Merger • July 29th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of July 29, 2021, by and among: Bioventus Inc., a Delaware corporation (“Parent”); Oyster Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Acquisition Sub I”), Oyster Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (“Acquisition Sub II,” and together with Acquisition Sub I, the “Acquisition Subs”); and Misonix, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

BIOVENTUS INC. STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT
Stock Option Agreement • July 19th, 2016 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

Bioventus Inc., a Delaware corporation (the “Company”), pursuant to its 2016 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). The Option is subject to the terms and conditions set forth in this Stock Option Grant Notice (this “Grant Notice”) and the Stock Option Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Option Agreement.

BIOVENTUS LLC PHANTOM PROFITS INTERESTS PLAN AWARD AGREEMENT
Award Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

This Bioventus LLC Phantom Profits Interests Plan Award Agreement (this “Award Agreement”), dated as of April 21, 2016 (the “Effective Date”), is delivered by Bioventus LLC (the “Company”) to Alessandra Pavesio (the “Grantee”).

AMENDMENT NO. 1 TO THE SECOND LIEN CREDIT AGREEMENT
Credit Agreement • July 19th, 2016 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

SECOND LIEN CREDIT AGREEMENT (this “Agreement”), dated as of October 10, 2014, among BIOVENTUS LLC, a Delaware limited liability company (the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (the “Lenders”) and CITIZENS BANK, N.A., as administrative agent.

AMENDMENT NO. 4 TO CREDIT AND GUARANTY AGREEMENT
Credit and Guaranty Agreement • March 31st, 2023 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

This CREDIT AND GUARANTY AGREEMENT, dated as of December 6, 2019, is entered into (as amended by that certain Amendment No. 1 to Credit and Guaranty Agreement dated as of August 29, 2021, Amendment No. 2 to Credit and Guaranty Agreement dated as of October 29, 2021, Amendment No. 3 to Credit and Guaranty Agreement dated as of July 11, 2022 and Amendment No. 4 to Credit and Guaranty Agreement dated as of March 31, 2023), is by and among Bioventus LLC, a Delaware limited liability company (“Borrower”), certain Subsidiaries of the Borrower from time to time party hereto, as Guarantor Subsidiaries, the Lenders from time to time party hereto and Wells Fargo Bank, National Association, as administrative agent (together with its permitted successors in such capacity, the “Administrative Agent”) and as collateral agent (together with its permitted successors in such capacity, the “Collateral Agent”).

Bioventus 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA 1-919-474-6700 1-800-396-4325 www.BioventusGlobal.com
Employment Letter Agreement • February 10th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • North Carolina

This Employment Letter Agreement (this “Agreement”) is entered into by and between you, Bioventus Inc. (the “Corporation”) and Bioventus LLC (the “Partnership” and, together with the Corporation and any of the affiliates of the Corporation or the Partnership as may employ you from time to time, “Bioventus”). This Agreement is an amendment and restatement of the certain Employment Offer letter dated as of November 18, 2016 by and between you and the Partnership, pursuant to which you are employed as the Chief Commercial Officer of the Partnership (the “Prior Agreement”) and supersedes the Prior Agreement in its entirety, effective as of the date of the consummation of the initial public offering of the Corporation’s common stock (the “Effective Date”).

VOTING AND SUPPORT AGREEMENT
Voting and Support Agreement • July 29th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of July 29, 2021, by and between Misonix, Inc., a Delaware corporation (the “Company”), and the persons set forth on Schedule A attached hereto (each, a “Stockholder” and, collectively, the “Stockholders”). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), by and among the Company, Bioventus Inc., a Delaware corporation (“Parent”), Oyster Merger Sub I, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Acquisition Sub I”) and Oyster Merger Sub II, LLC, a Delaware limited liability company and a wholly owned Subsidiary of Parent (“Acquisition Sub II”).

STOCKHOLDERS AGREEMENT
Stockholders Agreement • February 17th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

THIS STOCKHOLDERS AGREEMENT, dated as of February 16, 2021 (as it may be amended, amended and restated or otherwise modified from time to time in accordance with the terms hereof, this “Agreement”), is entered into by and among (i) Bioventus Inc., a Delaware corporation (the “Company”), (ii) Bioventus LLC, a Delaware limited liability company (“Bioventus LLC”), (iii) the entities listed on Schedule 1 attached hereto (together with their Affiliates, collectively, the “Essex Stockholders”) and (iv) the entities listed on Schedule 2 attached hereto (together with their Affiliates, collectively, the “S+N Stockholders” and, together with the Essex Stockholders, the “Principal Stockholders” and each a “Principal Stockholder”). Capitalized terms used herein without definition shall have the meanings set forth in Section 1.1.

Bloventus LLC 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA 1-919-474-6700 1-800-396-4325 www.BioventusGlobal.com
Letter Agreement • July 25th, 2016 • Bioventus Inc. • Surgical & medical instruments & apparatus • North Carolina

This letter agreement (the “Agreement”) sets forth the terms of your continued employment at Bioventus LLC (“Bioventus” or the “Company”). This Agreement will be effective on the effective date of the initial public offering of Bioventus Inc. common stock (the “IPO”) and will supersede in its entirety that certain offer letter entered into by and between you and Bioventus LLC dated September 27, 2012.

FIRST LIEN CREDIT AGREEMENT among BIOVENTUS LLC, as Borrower, The Several Lenders from Time to Time Parties Hereto, HSBC BANK USA, NATIONAL ASSOCIATION, CITIZENS BANK, N.A. and BBVA COMPASS, as Co-Syndication Agents and JPMORGAN CHASE BANK, N.A., as...
First Lien Credit Agreement • July 19th, 2016 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

FIRST LIEN CREDIT AGREEMENT (this “Agreement”), dated as of October 10, 2014, among BIOVENTUS LLC, a Delaware limited liability company (the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (the “Lenders”) and JPMORGAN CHASE BANK, N.A., as administrative agent.

SECOND LIEN CREDIT AGREEMENT among BIOVENTUS LLC, as Borrower, The Several Lenders from Time to Time Parties Hereto, JPMORGAN CHASE BANK, N.A, as Syndication Agent and CITIZENS BANK, N.A., as Administrative Agent Dated as of October 10, 2014 J.P....
Second Lien Credit Agreement • July 19th, 2016 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

SECOND LIEN CREDIT AGREEMENT (this “Agreement”), dated as of October 10, 2014, among BIOVENTUS LLC, a Delaware limited liability company (the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (the “Lenders”) and CITIZENS BANK, N.A., as administrative agent.

BIOVENTUS LLC PHANTOM PROFITS INTERESTS PLAN AWARD AGREEMENT
Award Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

This Bioventus LLC Phantom Profits Interests Plan Award Agreement (this “Award Agreement”), dated as of June 1, 2015 (the “Effective Date”), is delivered by Bioventus LLC (the “Company”) to Alessandra Pavesio (the “Grantee”).

April 24, 2020 Ken Reali Re: Amendment to Employment Agreement Dear Ken:
Employment Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus

This letter will serve to amend your employment agreement with Bioventus LLC dated as of March 14, 2020 (the “Agreement”) as follows:

BIOVENTUS LLC AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT dated as of May 4, 2012 among SMITH & NEPHEW, INC., BELUGA I, INC., BELUGA II, INC., BELUGA III, INC., BELUGA IV, INC., BELUGA V, INC., BELUGA VI, INC., BELUGA VII, INC., BELUGA...
Limited Liability Company Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

THIS AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”) of Bioventus LLC (the “Company”) is dated as of May 4, 2012 among the Company, Smith & Nephew, Inc., a Delaware corporation (“S&N”), Beluga I, Inc., a Delaware corporation (“Beluga I”), Beluga II, Inc., a Delaware corporation (“Beluga II”), Beluga III, Inc., a Delaware corporation (“Beluga III”), Beluga IV, Inc., a Delaware corporation (“Beluga IV”), Beluga V, Inc., a Delaware corporation (“Beluga V”), Beluga VI, Inc., a Delaware corporation (“Beluga VI”), Beluga VII, Inc., a Delaware corporation (“Beluga VII”), Beluga VII-A, Inc., a Delaware corporation (“Beluga VII-A”), Beluga VIII, Inc., a Delaware corporation (“Beluga VIII”), Mark A. Augusti and each other Member listed on the signature pages hereto from time to time.

SUMMARY OF MANAGEMENT INCENTIVE PLAN AWARD AGREEMENT
Award Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

This Bioventus LLC Management Incentive Plan Award Agreement (this “Award Agreement”), dated as of December 2, 2013 (the “Effective Date”), is delivered by Bioventus LLC (the “Company”) to Anthony P. Bihl III (the “Grantee”)

AMENDED AND RESTATED LICENSE AGREEMENT – US BETWEEN BIOVENTUS LLC AND Q-MED AB AND NESTLÉ SKIN HEALTH S.A. December 9, 2016
License Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

This Amended and Restated License Agreement – US (together with all schedules and exhibits attached hereto, the “Agreement”), is made and entered into this December 9, 2016 (the “Amendment Effective Date”), by and among Q-Med AB, a limited liability company organized under the laws of the Kingdom of Sweden with corporate registration number 556258-6882 (“Q-Med”), Nestlé Skin Health S.A., a corporation organized under the laws of Switzerland (“NSH”), and Bioventus LLC, a limited liability company organized under the laws of Delaware (“Bioventus”). Each of (i) Q-Med and NSH, on the one hand, and (ii) Bioventus, on the other hand, shall be referred to herein as a “Party” and collectively as the “Parties.” This Agreement shall amend, supersede and replace the Current US License Agreement (as defined below).

Bioventus Inc. [•] Shares of Class A Common Stock Underwriting Agreement
Bioventus Inc. • February 4th, 2021 • Surgical & medical instruments & apparatus • New York

Bioventus Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of Class A common stock, par value $0.001 per share (“Class A Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Class A Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Class A Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.

AutoNDA by SimpleDocs
AMENDED AND RESTATED SUPPLY AGREEMENT - US BETWEEN BIOVENTUS LLC AND Q-MED AB December 9, 2016
Supply Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

This Amended and Restated Supply Agreement – US (together with all schedules and exhibits attached hereto, this “Agreement”) is entered into as of December 9, 2016 (the “Amendment Effective Date”), between Bioventus LLC, a limited liability company organized under the laws of Delaware (“Bioventus”), Q-Med AB, a limited liability company organized under the laws of the Kingdom of Sweden with corporate registration number 556258-6882 (“Q-Med”) and Nestlé Skin Health S.A., a corporation organized under the laws of Switzerland, as guarantor of Q-Med’s obligations hereunder (“Guarantor”). Each of (i) Q-Med and Guarantor, on the one hand, and (ii) Bioventus, on the other hand, shall be referred to herein as a “Party” and collectively as the “Parties.” This Agreement shall amend, supersede and replace the Current US Supply License Agreement (as defined below).

Bioventus 1-919-474-6700
Restrictive Covenant Agreement • April 11th, 2023 • Bioventus Inc. • Surgical & medical instruments & apparatus • North Carolina
Contract
License, Supply and Distribution Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

AMENDMENT TO OPTION AND EQUITY PURCHASE AGREEMENT
Option and Equity Purchase Agreement • June 22nd, 2022 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

THIS AMENDMENT (this “Amendment”), entered into and effective as of June 17, 2022, is made by and among (a) Bioventus LLC, a Delaware limited liability company (“Buyer”), (b) CartiHeal (2009) Ltd., an Israeli private company registered under number 514279645 (the “Company”) and (c) Elron Ventures Ltd. (formerly known as Elron Electronic Industries Ltd.), an Israeli public company, in its capacity as the Securityholder Representative (the “Securityholder Representative”), and amends that certain Option and Equity Purchase Agreement (the “Agreement”), dated July 15, 2020, by and among Buyer, the Company, the Securityholder Representative and the Securityholders party thereto. Buyer, the Company and the Securityholder Representative are collectively referred to herein as the “Parties” and, each individually, as a “Party.” Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Agreement.

SETTLEMENT AGREEMENT
Settlement Agreement • March 26th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus

This Settlement Agreement (“Agreement”) is entered into between the United States of America, acting through the United States Attorney’s Office for the Middle District of North Carolina and on behalf of the Office of Inspector General of the Department of Health and Human Services (“OIG-HHS”) (collectively the “United States”), and Bioventus LLC (“Bioventus”), through their authorized representatives. Collectively, all of the above will be referred to as “the Parties.”

Bioventus LLC 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA 1-919-474-6700 1-800-396-4325 www.BioventusGlobal.com
Non-Competition Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • North Carolina

You will be employed in the role of Chief Science Officer and you shall perform the duties of this role as are customary and as may be required by Bioventus. You will report to the Chief Executive Officer, Mark Augusti, and you will be based at the headquarters of Bioventus currently located in Durham, NC.

ASSIGNMENT AND ASSUMPTION AGREEMENT
Assignment and Assumption Agreement • July 19th, 2016 • Bioventus Inc. • Surgical & medical instruments & apparatus

This ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), dated as of July [ ], 2016, and effective as of the Effective Date (defined below), is hereby entered into by and among Bioventus LLC, a Delaware limited liability company (“Assignor”), and Bioventus Inc. (“Assignee”).

Bioventus LLC 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA 1-919-474-6700 1-800-396-4325 www.BioventusGlobal.com
Non-Competition Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • North Carolina

You will be employed in the role of Chief Executive Officer and you shall perform the duties of this role as are customary and as may be required by Bioventus. You will report to the Board and you will be based at the headquarters of Bioventus currently located in Durham, NC.

AMENDED AND RESTATED EXCLUSIVE DISTRIBUTION AGREEMENT BETWEEN SEIKAGAKU CORPORATION AND BIOVENTUS LLC RESTATED AS OF MAY 4 , 2012
Bioventus Inc. • July 27th, 2016 • Surgical & medical instruments & apparatus • New York

Amended and Restated Exclusive Distribution Agreement, as restated to include all amendments in effect as of May 4, 2012 (the “Effective Date”), (as so restated, this “Agreement”) by and between BIOVENTUS LLC, a Delaware limited liability company having its principal place of business at 4721 Emperor Boulevard, Durham, NC 27703 (“Distributor”), and SEIKAGAKU CORPORATION, a Japanese corporation having its principal place of business at Marunouchi Center Building, 6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-0005, Japan (“Company”). Distributor and Company are sometimes referred to herein individually as a “Party” and are sometimes referred to herein collectively as the “Parties.”

OPTION AND EQUITY PURCHASE AGREEMENT by and among BIOVENTUS LLC, CARTIHEAL (2009) LTD., THE MAJOR SECURITYHOLDERS AND ELRON ELECTRONIC INDUSTRIES LTD., AS THE SECURITYHOLDER REPRESENTATIVE, DATED AS OF JULY 15, 2020
Option and Equity Purchase Agreement • January 20th, 2021 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

This Option and Equity Purchase Agreement (this “Agreement”), dated as of July 15, 2020, is entered into by and among (a) Bioventus LLC, a Delaware limited liability company (“Buyer”), (b) CartiHeal (2009) Ltd., an Israeli private company registered under number 514279645 (the “Company”), (c) the Securityholders set forth on Schedule 1.01(a) hereto (the “Major Securityholders”) and each other Securityholder that becomes a party hereto following the date of this Agreement pursuant to a Joinder Agreement and (c) Elron Electronic Industries Ltd., an Israeli public company, in its capacity as the Securityholder Representative. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section 1.01.

AMENDMENT NO. 5 TO CREDIT AND GUARANTY AGREEMENT
Credit and Guaranty Agreement • January 19th, 2024 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York

This CREDIT AND GUARANTY AGREEMENT, dated as of December 6, 2019 (as amended by that certain Amendment No. 1 to Credit and Guaranty Agreement dated as of August 29, 2021, Amendment No. 2 to Credit and Guaranty Agreement dated as of October 29, 2021, Amendment No. 3 to Credit and Guaranty Agreement dated as of July 11, 2022 and, Amendment No. 4 to Credit and Guaranty Agreement dated as of March 31, 2023, and Amendment No. 5 to Credit and Guaranty Agreement dated as of January 18, 2024), is by and among Bioventus LLC, a Delaware limited liability company (“Borrower”), certain Subsidiaries of the Borrower from time to time party hereto, as Guarantor Subsidiaries, the Lenders from time to time party hereto and Wells Fargo Bank, National Association, as administrative agent (together with its permitted successors in such capacity, the “Administrative Agent”) and as collateral agent (together with its permitted successors in such capacity, the “Collateral Agent”).

BIOVENTUS INC. DIRECTOR RESTRICTED STOCK UNIT AWARD GRANT NOTICE
Director Restricted Stock Unit Award Grant Notice • July 19th, 2016 • Bioventus Inc. • Surgical & medical instruments & apparatus • Delaware

Bioventus Inc., a Delaware corporation (the “Company”), pursuant to its 2016 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of Restricted Stock Units (the “RSUs”) set forth below. The RSUs are subject to the terms and conditions set forth in this Restricted Stock Unit Grant Notice (the “Grant Notice”) and the Restricted Stock Unit Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement.

Bioventus LLC 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA 1-919-474-6700 1-800-396-4325 www.BioventusGlobal.com
Bioventus Inc. • January 20th, 2021 • Surgical & medical instruments & apparatus • North Carolina

You will be employed in the role of Chief Executive Officer and you shall perform the duties of this role as are customary and as may be required by Bioventus. You will report to the Board of Managers of the company, and you will be based at the headquarters of Bioventus currently located in Durham, NC.

Time is Money Join Law Insider Premium to draft better contracts faster.